October 14, 2020
PK/PD Relationship in Targeted Protein Degradation
3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Rong
Read More
October 9, 2020
Interim results from non-interventional study to evaluate cutaneous and circulating biomarkers for a novel IRAK4-targeted therapeutic in patients with hidradenitis suppurativa
5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
Hidradenitis Suppurativa (HS)
Read More
June 22, 2020
IRAKIMiDs: Protein degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broad activity with durable regressions in MYD88 mutant lymphoma xenografts in vivo
American Association for Cancer Research (AACR) Virtual Annual Meeting II
MYD88 Tumors
Read More
June 22, 2020
A STAT3-selective targeted protein degrader decreases the immune-suppressive tumor microenvironment and drives anti-tumor activity in preclinical models
American Association for Cancer Research (AACR) Virtual Annual Meeting II
Liquid Tumors
Solid Tumors
Read More
February 5, 2020
Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa
European Hidradenitis Suppurativa Foundation Scientific Conference
Hidradenitis Suppurativa (HS)
Read More
December 7, 2019
Small molecule-induced, selective STAT3 degradation leads to anti-tumor activity in STAT3-dependent heme malignancies
American Society of Hematology (ASH) Annual Meeting
Liquid Tumors
Read More
November 8, 2019
A first-in-class selective and potent IRAK4 degrader demonstrates robust in vitro and in vivo inhibition of TLR/IL-1R activation and inflammation
American College of Rheumatology Annual Meeting
Read More
October 26, 2019
Discovery of KYM-003, a potent and selective STAT3 degrader with anti-tumor activity in heme malignancies
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Liquid Tumors
Read More
June 18, 2019
IRAK4 degraders for MYD88 mutant lymphoma
International Conference on Malignant Lymphoma (ICML)
MYD88 Tumors
Read More
March 29, 2019
KYM-001, first-in-class oral IRAK4 protein degraders, induce tumor regression in a xenograft model of MYD-88 mutant ABC DLBCL alone and in combination with BTK inhibition
American Association for Cancer Research (AACR) Annual Meeting
MYD88 Tumors
Read More